BNP Paribas Asset Management
CSTL icon

BNP Paribas Asset Management’s Castle Biosciences CSTL Stock Holding History

BNP Paribas Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9K Sell
707
-54
-7% -$1.2K ﹤0.01% 2092
2026
Q1 		$18.7K Sell
761
-1,078
-59% -$35.3K ﹤0.01% 2058
2025
Q4 		$72K Buy
1,839
+1,378
+299% +$44.4K ﹤0.01% 1559
2025
Q3 		$10K Buy
461
+33
+8% +$670 ﹤0.01% 1625
2025
Q2 		$9K Buy
+428
New +$7.92K ﹤0.01% 1804

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's CSTL Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Castle Biosciences (CSTL) stake by 7.1% in Q2 2026, selling an estimated $1.2K and leaving 707 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2092.

BNP Paribas Asset Management first reported a position in CSTL in Q2 2025 and has held it in 5 quarters since. The position peaked at $72K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • BNP Paribas Asset Management held 707 shares of Castle Biosciences worth $16.9K as of Q2 2026.
  • BNP Paribas Asset Management sold 54 Castle Biosciences shares in Q2 2026, an estimated $1.2K.
  • Castle Biosciences made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2092 holding.
  • BNP Paribas Asset Management first reported a position in Castle Biosciences in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's Castle Biosciences position peaked at $72K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.